- Triomics secures $15M Series A funding to streamline cancer clinical trials matching.
- Only 3-5% of eligible cancer patients enroll in clinical trials annually in the US.
- Triomics utilizes generative AI to expedite patient-trial matching, addressing the time constraints faced by oncologists.
- Founded by Sarim Khan and Hrituraj Singh in 2021, Triomics aims to leverage AI and LLMs to extract data from electronic health records (EHR).
- Triomics’ OncoLLM platform is adopted by six cancer centers and hospitals, with plans for expansion.
- Investors include Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator.
Main AI News:
In the realm of cancer treatment, clinical trials often serve as a beacon of hope, potentially extending or saving lives for patients in need. However, despite the multitude of trials conducted annually in the United States, merely 3% to 5% of eligible patients participate in these pivotal investigations.
Triomics, a burgeoning generative AI firm, asserts its capability to significantly truncate the time required for physicians to pair patients with suitable trials. The crux of the issue lies in the constraints faced by busy oncologists and nurses, who frequently grapple with time constraints hindering their ability to sift through the plethora of available clinical trials.
The genesis of Triomics stemmed from the personal experiences of its founders, Sarim Khan and Hrituraj Singh. With a shared vision, Khan and Singh embarked on a mission to harness the power of generative AI and LLMs to streamline the arduous process of extracting pertinent data from electronic health records (EHR), thereby expediting the identification of fitting clinical trials for cancer patients.
Following their inception in 2021, Khan and Singh joined forces with Y Combinator to further cultivate their brainchild. Fast forward to the present day, Triomics boasts adoption by six cancer centers and hospitals, with plans to double its reach by year-end. The recent injection of $15 million in Series A funding from Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator underscores investor confidence in Triomics’ potential to revolutionize cancer care.
While Triomics’ primary focus revolves around expediting patient-trial matching, Khan emphasizes that their platform offers multifaceted utility beyond clinical trials alone. Dubbed OncoLLM, Triomics’ proprietary LLM holds promise in aiding physicians in various capacities, from prepping for patient consultations to facilitating regulatory compliance by parsing intricate medical data.
In an industry teeming with AI-driven solutions, Triomics stands out for its tailored approach to cancer center datasets. While competitors abound, Triomics’ commitment to processing extensive datasets with a laser focus on cancer care sets it apart as a frontrunner in the field.
Conclusion:
Triomics’ successful Series A funding signifies a significant advancement in the market for AI-driven solutions in cancer care. By addressing the critical need for expeditious patient-trial matching, Triomics not only enhances patient outcomes but also establishes itself as a frontrunner in leveraging AI technology to revolutionize cancer treatment. This funding injection not only bolsters Triomics’ development but also underscores investor confidence in the burgeoning market for healthcare AI solutions.
